Method to treat chronic heart failure and/or elevated cholesterol levels

• US 20030147815A1
• Filed: 02/18/2003
• Published: 08/07/2003
• Est. Priority Date: 01/31/2001
• Status: Active Grant

• Current Assignee: Arizona Board of Regents (University of Arizona)
• Original Assignee: Arizona Board of Regents (University of Arizona)
• Inventors: Morkin, Eugene
• Granted Patent: US 6,716,877 B2
• Time in Patent Office: Days
• US Class Current: 424/45
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/195 having an amino group
• CPC Class Codes: A61K 9/4866 Organic macromolecular compounds
• CPC Class Codes: A61K 9/7023 Transdermal patches and similar drug-containing composite devices, e.g. cataplasms galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006
• CPC Class Codes: A61P 3/06 Antihyperlipidemics
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Abstract

A method for treating a patient having congestive heart failure by administering a therapeutically effective amount of 3′,3,5-triiodothyropropionic acid (TRIPROP) or 3,5,3′,5′-tetraiodothyropropionic acid (TETRAPROP). Also described is a method to lower cholesterol blood levels of a patient by administering a therapeutically effective amounts of TRIPROP or TETRAPROP.

Claims

1. A method for treatment of a patient with congestive heart failure, comprising administering to the patient a therapeutically effective amount of 3′

,3,5-triiodothyropropionic acid or 3,5,3′

,5′

-tetraiodothyropropionic acid.

2. The method of claim 1, wherein 3′

,3,5-triiodothyropropionic acid or 3,5,3′

,5′

-tetraiodothyropropionic acid is administered as a formulation selected from the group consisting of a liquid preparation, solid preparation, capsule preparation, and an implant preparation.

3. The method of claim 2, wherein said formulation further comprises a pharmaceutically acceptable carrier.

4. The method of claim 3, wherein said formulation further comprises at least one of a stabilizer, excipient, solubilizer, antioxidant, pain-alleviating agent, and an isotonic agent.

5. The method of claim 1, wherein said 3′

,3,5-triiodothyropropionic acid or 3,5,3′

,5′

-tetraiodothyropropionic acid is administered by parenteral injection.

6. The method of claim 5, wherein said 3′

,3,5-triiodothyropropionic acid or 3,5,3′

,5′

-tetraiodothyropropionic acid is administered by parenteral intravenous injection.

7. The method of claim 1, wherein said 3′

,3,5-triiodothyropropionic acid or 3,5,3′

,5′

-tetraiodothyropropionic acid is administered orally.

8. The method of claim 1, wherein said 3′

,3,5-triiodothyropropionic acid or 3,5,3′

,5′

-tetraiodothyropropionic acid is administered directly to the pulmonary system of the patient.

9. The method of claim 1, wherein said 3′

,3,5-triiodothyropropionic acid or 3,5,3′

,5′

-tetraiodothyropropionic acid is administered transdermally.

10. The method of claim 1, wherein said 3′

,3,5-triiodothyropropionic acid or 3,5,3′

,5′

-tetraiodothyropropionic acid is administered by implantation.

11. A method to lower cholesterol blood levels of a patient, comprising administering to the patient a therapeutically effective amount of 3′

,3,5-triiodothyropropionic acid or 3,5,3′

,5′

-tetraiodothyropropionic acid.

12. The method of claim 11, wherein 3′

,3,5-triiodothyropropionic acid or 3,5,3′

,5′

-tetraiodothyropropionic acid is administered as a formulation selected from the group consisting of a liquid preparation, solid preparation, capsule preparation, and an implant preparation.

13. The method of claim 12, wherein said formulation further comprises a pharmaceutically acceptable carrier.

14. The method of claim 13, wherein said formulation further comprises at least one of a stabilizer, excipient, solubilizer, antioxidant, pain-alleviating agent, and an isotonic agent.

15. The method of claim 11, wherein said 3′

,3,5-triiodothyropropionic acid or 3,5,3′

,5′

-tetraiodothyropropionic acid is administered by parenteral injection.

16. The method of claim 15, wherein said 3′

,3,5-triiodothyropropionic acid or 3,5,3′

,5′

-tetraiodothyropropionic acid is administered by parenteral intravenous injection.

17. The method of claim 11, wherein said 3′

,3,5-triiodothyropropionic acid or 3,5,3′

,5′

-tetraiodothyropropionic acid is administered orally.

18. The method of claim 11, wherein said 3′

,3,5-triiodothyropropionic acid or 3,5,3′

,5′

-tetraiodothyropropionic acid is administered directly to the pulmonary system of the patient.

19. The method of claim 11, wherein said 3′

,3,5-triiodothyropropionic acid or 3,5,3′

,5′

-tetraiodothyropropionic acid is administered transdermally.

20. The method of claim 11, wherein said 3′

,3,5-triiodothyropropionic acid or 3,5,3′

,5′

-tetraiodothyropropionic acid is administered by implantation.